BRUKINSA works to help you take control of your MZL

BRUKINSA is a BTK inhibitor that
was designed to block BTK

  • BRUKINSA has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of blocking up to 100% of BTK on treatment responses has not been established

Why is a BTK inhibitor important for
marginal zone lymphoma (MZL) treatment?

MZL is caused by rapid growth and spread of cancerous B cells.

  • Bruton’s tyrosine kinase (BTK) is a protein that signals to cancerous B cells, helping them to grow and spread
  • Blocking BTK can help stop this signaling

The significance of blocking up to 100% of BTK on treatment responses has not been established.

How well does BRUKINSA work?

In 2 clinical studies, 88 patients with MZL received BRUKINSA
after at least 1 prior therapy. In both clinical studies:

More than
56
responded to treatment,
known as the overall response rate
Nearly
72
continued to respond
for a year or longer

The effectiveness of BRUKINSA may vary for different people.

What are the possible side effects of BRUKINSA?

BRUKINSA may cause serious side effects, including:

Bleeding problems (hemorrhage) that can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:

  • blood in your stools or black stools (looks like tar)
  • pink or brown urine
  • unexpected bleeding, or bleeding that is severe or you cannot control
  • vomit blood or vomit that looks like coffee grounds
  • cough up blood or blood clots
  • increased bruising
  • dizziness
  • weakness
  • confusion
  • change in speech
  • headache that lasts a long time

Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.

Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with BRUKINSA, but can also be severe. Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.

Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.

Heart rhythm problems (atrial fibrillation and atrial flutter). Tell your healthcare provider if you have any of the following signs or symptoms:

  • your heartbeat is fast or irregular
  • feel lightheaded or dizzy
  • pass out (faint)
  • shortness of breath
  • chest discomfort

What are the most common side effects?

The most common side effects of BRUKINSA include:

Decreased white blood cells

Upper respiratory tract infection

Decreased platelet count

Bleeding

Rash

Muscle or joint pain


6% of patients discontinued treatment due to side effects in the trials.

These are not all the possible side effects of BRUKINSA.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.


How long will I be on treatment with BRUKINSA?

You will take BRUKINSA for as long as your doctor thinks it is helping you, or for as long as side effects are manageable.

About 15 months was the median duration of treatment for patients in the clinical studies. The median marks the midpoint where half of the patients were still taking BRUKINSA, while half were no longer on treatment.

Remember, everyone responds differently to treatment, so the length of time that you take BRUKINSA could be shorter or longer.

Patient Support Program

Call 1-833-234-4363 to talk with an Oncology Nurse Advocate.
Oncology Nurse Advocates are available 8 AM-8 PM ET
Monday through Friday.

Learn More
BRUKINSA FOR MZLTAKING BRUKINSA